BORDETELLA PERTUSSIS IMMUNOGENIC VACCINE COMPOSITIONS

摘要

This invention is directed to composition, vaccines, tools and methods in the treatment and prevention of Bordetella pertussis. In particular, the invention is directed to a three-pronged approach that involves removal of the nonessential vaccine components, use of a nondenatured, genetically detoxified mutant, and adding virulence factors.

主权项

1. An immunogenic B pertussis vaccine composition comprising a genetically detoxified pertussis toxin (PT); a genetically detoxified pertussis adenylate cyclase toxin (ACT); an immunogenic oligosaccharide or fragment thereof derived from the lipooligosaccharide of B pertussis having one or more of the antigenic determinants of the endotoxin to a carrier protein or peptide; a TLR agonist to induce a protective cell-mediated response against B pertussis wherein when provided to a mammal said composition:
produces neutralizing anti toxin antibodies against B pertussis; produces direct bactericidal antibodies against B pertussis; elicits a pertussis toxin-specific Th1/Th17 cell response; generates IFN-6 and IL-17 cytokines wherein said cytokines permit recruitment of neutrophils; and reduces nasopharyngeal colonization and carriage of B. pertussis in the vaccine recipient.